Rahul Sahgal – CEO, Swiss-American Chamber of Commerce
Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to…
The Swiss-American Chamber of Commerce plays a vital and active role in assisting Swiss companies in the United States and U.S. companies in Switzerland to expand their business. The Swiss-American Chamber of Commerce is a not-for-profit organization.
Relations between Switzerland and the United States of America are extremely diverse and enjoy a rich tradition. The United States is the second largest export market for Switzerland and an important hub for education and research. Over the last 12 years, exports to America have doubled in volume, going from 10.6 to 14.5 percent of all Swiss exports between 2004 and today. Swiss pharmaceutical exports account for approximately 47 percent of trade with America.
Contact
Talacker 41, 8001 Zurich, Switzerland, Phone: +41 43 443 72 00
Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to…
In a wide-ranging conversation, Martin Naville of AmCham Switzerland looks at the evolution of the Switzerland-US trade relationship and the importance of pharma within it, the pressing need for a…
Martin Naville, CEO of the Swiss-American Chamber of Commerce, discusses Swiss exports to the US, global competitiveness and innovation rankings, and why the Swiss-US relationship will only continue to grow…
The small Italian-speaking Canton of Ticino, nestled away in Southern Switzerland, is fast developing its reputation as a life sciences hub which – if not able to compete directly with…
Regarded as one of the world’s leading regulatory bodies, Swissmedic stands alongside its equivalents in Europe, Japan, Canada, and Australia in terms of the evaluation and approval of new drugs,…
Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of…
Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide, forming collaborations between entrepreneurs and the Johnson & Johnson Family of Companies’ global healthcare businesses. Michael Hübner, Early…
While once considered the land of milk and honey within Europe in terms of market access and reimbursement for innovative pharmaceuticals, Switzerland is increasingly tightening its belt on this front…
Stefan Berg, general manager of Pharmaplan, one of the leading pharma engineering partners in Europe, outlines the key trends in this area, including an expected investment boom in the coming…
Merck Switzerland’s Christiane von der Eltz highlights the German firm’s recent big investments in Switzerland and how it forms a key part of Merck’s global research and manufacturing networks. von…
Dr Michael Bauer, a Novartis early development veteran, now serves as CEO of Basel-based Cellestia. Here, Bauer explains why Cellestia’s unique transcription factor targeting molecule potentially represents a breakthrough in…
The Novartis and Roche names are synonymous with Swiss pharmaceutical innovation. But for these two Basel-based global behemoths, what value does Switzerland itself hold and what do they see as…
Fabian Gerber of SIX Swiss Exchange, Switzerland’s principal stock exchange, outlines the importance of life sciences companies to the exchange, representing over a third of total market capitalization with the…
Josua Jordi of Swiss biotech EraCal explains the company’s technology platform, their work with zebrafish larvae to find a biologic mechanism to control appetite, and how it compares with the…
Interpharma’s Dr René P. Buholzer highlights the key lessons that Switzerland’s innovative pharmaceutical industry has taken from the COVID-19 pandemic, the challenges inherent in the country’s two upcoming cost containment…
See our Cookie Privacy Policy Here
